TENAX THERAPEUTICS, INC. (TENX): Nasdaq/NYSE listing notice — Tenax Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance

TENAX THERAPEUTICS, INC.

Nasdaq notified Tenax on March 29, 2023 that bid price closed below $1.00 for 30 consecutive business days.
Company has until September 25, 2023 to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured, Company may be eligible for additional 180-day period if it meets other listing standards.
No immediate effect on listing; stock continues trading under TENX on Nasdaq Capital Market.
Company evaluating options including potential reverse stock split to cure deficiency.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TENAX THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 29, 2023, Nasdaq Stock Market LLC (“Nasdaq”) notified Tenax Therapeutics, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until September 25, 2023, to regain compliance with the Bid Price Rule. If at any time before September 25, 2023

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001654954-23-003859

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.